Search for Clinical Trial Results

Sponsored By

Lymphoma, Mantle-Cell - 25 Studies Found

Status Study
Completed Study Name: Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
Condition: Lymphoma, Mantle-Cell
Date: 2002-06-03
Interventions:
  • Drug: Yttrium-ibritumomab (Zevalin)

Completed Study Name: Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)
Condition: Lymphoma, Mantle-Cell
Date: 2010-10-13
Interventions: Drug: Combination of dexamethasone, ofatumumab and bendamustine
Completed Study Name: An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
Condition: Lymphoma, Mantle-Cell
Date: 2007-01-05
Interventions: Drug: PD-0332991 125 mg, oral, Days 1-21 of a 28-day cycle
Completed Study Name: Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Lymphoma, Mantle-cell
Date: 2014-06-19
Interventions: Drug: Ibrutinib Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a
Completed Study Name: Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma
Condition: Lymphoma, Mantle-Cell
Date: 2009-10-07
Interventions: Drug: Rituximab, Bendamustine, Cytarabine Rituximab IV 375
Completed Study Name: Safety and Efficacy of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy.
Condition: Lymphoma, Mantle- Cell
Date: 2008-06-19
Interventions: Drug: RAD001
Completed Study Name: Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
Condition: Lymphoma, Mantle-Cell
Date: 2015-01-14
Recruiting Study Name: A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Condition: Lymphoma, Mantle Cell
Date: 2016-11-21
Interventions:
  • Drug: Acalabrutinib in combination with bendamustine and rituximab
Not yet recruiting Study Name: Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants
Condition: Lymphoma, Mantle-Cell
Date: 2017-02-10
Completed Study Name: Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
Condition: Lymphoma, Mantle-Cell
Date: 2009-10-08
Interventions: Biological: Tositumomab and Iodine I 131 Tositumomab followed by CHOP Patients will receive an infusion
Next >>>